FdaApplication
NDA 202810
Identifiers
- fda_app_no: NDA202810
Properties
| Property | Value |
|---|---|
| applicant_name | SUPERNUS PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2012-10-19 |
Revenue by product
OXTELLAR XR
| Period | Revenue |
|---|---|
| Q2 2026 | $8.8M |
| Q1 2026 | $7.4M |
| Q4 2025 | $6.8M |
| Q3 2025 | $12.0M |
| Q2 2025 | $11.6M |
| Q1 2025 | $10.2M |
| Q4 2024 | $13.2M |
| Q3 2024 | $29.8M |
| Q2 2024 | $29.5M |
| Q1 2024 | $26.9M |
| Q4 2023 | $31.0M |
| Q3 2023 | $29.6M |
| Q2 2023 | $23.8M |
| Q1 2023 | $28.9M |
| Q4 2022 | $27.3M |
| Q3 2022 | $30.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OXTELLAR XR | OXCARBAZEPINE | 600MG | TABLET, EXTENDED RELEASE;ORAL |
| OXTELLAR XR | OXCARBAZEPINE | 300MG | TABLET, EXTENDED RELEASE;ORAL |
| OXTELLAR XR | OXCARBAZEPINE | 150MG | TABLET, EXTENDED RELEASE;ORAL |
3 products